Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review highlights the potential of PROTAC technology in drug discovery for previously undruggable targets, particularly in cancer therapy, while emphasizing the urgent need to discover more E3 ligase recruiters to optimize targeted protein degradation.

This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.

This study developed a method for designing peptide-based PROTAC drugs using advanced AI models, successfully identifying peptides that bind to specific receptors and incorporating them into a potential transdermal treatment for androgenetic alopecia.

This article discusses the impact of PROTACs technology in transforming drug discovery with its novel degradation mechanism, but it reports no new experimental findings.

This review outlines advances in topical PROTACs for localized protein degradation, focusing on AH-001 and GT20029 for skin conditions, but presents no new clinical trial results.

This review examines the development and challenges of using PROTACs, a targeted protein degradation strategy, to treat cancer by degrading specific proteins like PARPs and GPX4, highlighting issues such as target diversification and bioavailability.

This study found that combining α 1A-blockers with Prozac was more effective for treating premature ejaculation than using Prozac alone.

This study found that MEGA PROTAC improved the prediction of ternary structures with higher maximum DockQ scores compared to the BOTCP method in 16 out of 22 test cases.

This review highlights how integrating medicinal chemistry with delivery science could transform the limitations of PROTACs—such as poor solubility and low cell permeability—into strengths, potentially advancing these compounds from experimental stages to clinical applications by optimizing their delivery and enhancing therapeutic efficacy.

This study developed nanoliposomes embedding AR-PROTAC and NFKBIZ siRNA to target androgen receptors and reduce oxidative stress, which improved the follicular microenvironment and enhanced hair regrowth in androgenetic alopecia, suggesting a promising multi-target therapeutic strategy.

In this study, researchers discovered a compound called C6 that exhibits excellent skin retention and androgen receptor degradation properties, significantly promoting hair regeneration in a mouse model of androgenetic alopecia following non-invasive topical application, suggesting potential for broader use of PROTACs in treating skin diseases.

This source reports on advances in stimulus-responsive nanoparticle-based PROTACs (nano-PROTACs), which aim to overcome existing challenges like poor cell permeability and systemic off-target effects by enabling controlled protein degradation through endogenous or exogenous stimuli, potentially enhancing therapeutic efficacy and reducing toxicity.

This review detailed the significant progress and challenges in the design and application of PROTACs, a novel class of cancer therapeutics, highlighting their clinical trials, design complexities, and the role of artificial intelligence in improving their efficacy and selectivity for cancer therapy.

This article discusses the potential for combining PROTACs with other therapeutic modalities in drug discovery and reports no clinical results.

This review highlights the potential of PROTACs to transform cancer treatment by selectively degrading oncogenic proteins, overcoming drug resistance, and reducing toxicity; it also discusses challenges in optimizing these therapies for personalized applications.

This review discusses the evolution of Cereblon ligands in PROTAC technology, highlighting chemical innovations that may enhance drug-likeness and applicability in protein degradation, while noting challenges and future research directions.

In this study, the authors developed a novel PROTAC named dAR-6–1, which demonstrated superior hair regeneration in an AGA mouse model compared to minoxidil, highlighting its promise as a therapy due to potent AR degradation and excellent skin permeability.

In this study, researchers presented a novel therapeutic approach for androgenetic alopecia combining AR-PROTAC degradation with regenerative strategies and evaluated the potential of GT20029 as a topical treatment, proposing a three-phase protocol and future research hypotheses.

This review identified emerging therapies for androgenetic alopecia, such as low-dose oral minoxidil and stem cell-based treatments, which show promise for improved hair loss management but require standardized protocols and large-scale trials for further validation.

This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.

This review highlights recent progress in developing androgen receptor degraders, such as PROTACs, for treating castration-resistant prostate cancer, and notes that several have entered phase I or II clinical trials, showcasing potential to address drug resistance challenges.

This study found that fluoxetine did not demonstrate short-term efficacy in treating trichotillomania in a placebo-controlled, double-blind crossover setting.

This review discusses cutaneous adverse effects of psychotropic medications and reports no new findings, emphasizing the importance of psychiatrists being aware of these potential skin reactions.

This review discusses recent advances in the pharmacological treatment of trichotillomania, highlighting potential benefits of glutamate-modulating agents, and reports no new clinical results.

In this study, fluoxetine was found to decrease proliferation and adipogenic differentiation of human adipose-derived stem cells, suggesting it may reduce fat accumulation by increasing autophagy-related gene expression.

This paper discusses the use of lifestyle drugs by individuals without medical conditions to enhance appearance, highlighting that such usage may worsen emotional disorders and suggests these should be treated with psychotherapy or psychopharmacotherapy.

This case report describes a 23-year-old Asian woman with fluoxetine non-responsive trichotillomania who showed significant improvement with bupropion and cognitive behavior therapy, though confirmation in larger trials is needed.

This report found that hair loss was extremely rare but occurred in some cases with certain antidepressants, notably fluoxetine and 5-HT uptake inhibitors, but not with trazodone or mianserin.

This study found that Adiantum capillus-veneris extract exhibited significant antidepressant and anti-anxiety effects in rats, likely due to its antioxidant and anti-inflammatory properties.

This study found that the antidepressant-like effect of fluoxetine in mice was only observed when a 5-minute pretest session was conducted, and this effect was blocked by the TSPO antagonist PK11195.